In our study, we found that samples with RYR2 mutation were more infiltrated by CD8 T cells, activated memory CD4 T cells, and M1 macrophages than samples with wild-type RYR2, indicating that RYR2 mutation may promote antitumor immunity in BC patients. The gene discussed is CD4; the disease is breast cancer.